Document is current
Any future updates will be listed below
-
Authors
Wei, Mingwei
Pan, Yu
Wang, Kangning
Li, Ming
Tang, Shaowen
Huang, Qianqian
Chen, Hongying
Kou, Zengqiang
Xie, Na
Guo, Xiang
An, Jing
Zhang, Jikai
Kezhong, A.
Chen, Yanjun
An, Youcai
Kang, Liuyang
Tao, Hang
Pan, Hongxing
-
Funding
Funding for this research was provided by:
The Center for Drug Reevaluation, NMPA (CDRZ20234001-2)
Ab&B Biotech Co., Ltd.
- License Information
-
More Information
Article History
Received: 12 March 2026
Accepted: 20 April 2026
First Online: 8 May 2026
Declarations
:
: All authors have declared no conflicts of interest. Hongxing Pan, Mingwei Wei, Yu Pan, Kangning Wang, Ming Li, Shaowen Tang, Qianqian Huang, Hongying Chen, Zengqiang Kou, Na Xie, Xiang Guo, Jing An, Jikai Zhang, A Kezhong and Yanjun Chen have nothing to disclose. Youcai An, Liuyang Kang and Hang Tao are employees of Ab&B Biotech Co., Ltd.
: This study adheres to the ethical principles for medical research involving human participants as outlined in the Declaration of Helsinki. This study was reviewed and approved by the Ethics Committees of the Provincial and Municipal Centers for Disease Control and Prevention in Jiangsu (JSJK2023-B016-02), Shanghai (KY-2023-58), Shandong (SDJK2023-036-02), Guangdong (2023V004-F), Hubei (2023-022-02), Xinjiang (P2024-002), Gansu (use JSJK2023-B016-02 for filing), and Qinghai (use JSJK2023-B016-02 for filing).
